IRIS
PALA, Daniele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.726
AS - Asia 1.457
EU - Europa 1.343
SA - Sud America 195
AF - Africa 78
OC - Oceania 1
Totale 4.800
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.680
SG - Singapore 553
CN - Cina 536
FI - Finlandia 319
IE - Irlanda 244
IT - Italia 226
SE - Svezia 207
BR - Brasile 157
DE - Germania 133
HK - Hong Kong 116
TR - Turchia 78
VN - Vietnam 73
NL - Olanda 47
ZA - Sudafrica 44
FR - Francia 35
GB - Regno Unito 33
IN - India 27
CA - Canada 23
BE - Belgio 22
CI - Costa d'Avorio 22
AR - Argentina 21
UA - Ucraina 20
MX - Messico 16
RU - Federazione Russa 13
JP - Giappone 12
BD - Bangladesh 8
ES - Italia 8
ID - Indonesia 8
CZ - Repubblica Ceca 7
IQ - Iraq 7
LT - Lituania 7
PK - Pakistan 6
MA - Marocco 5
VE - Venezuela 5
EC - Ecuador 4
JO - Giordania 4
PL - Polonia 4
HU - Ungheria 3
IL - Israele 3
PS - Palestinian Territory 3
PY - Paraguay 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AT - Austria 2
AZ - Azerbaigian 2
CL - Cile 2
CO - Colombia 2
HN - Honduras 2
KE - Kenya 2
KG - Kirghizistan 2
KR - Corea 2
LV - Lettonia 2
MD - Moldavia 2
MY - Malesia 2
NP - Nepal 2
TN - Tunisia 2
TW - Taiwan 2
AM - Armenia 1
AO - Angola 1
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
CH - Svizzera 1
CY - Cipro 1
DO - Repubblica Dominicana 1
EE - Estonia 1
EG - Egitto 1
GR - Grecia 1
GT - Guatemala 1
LK - Sri Lanka 1
NI - Nicaragua 1
NO - Norvegia 1
OM - Oman 1
PA - Panama 1
PH - Filippine 1
RO - Romania 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TV - Tuvalu 1
UZ - Uzbekistan 1
VG - Isole Vergini Britanniche 1
Totale 4.800
Salva come PNG Salva come JPEG
Città #
Singapore 276
Dublin 244
Chandler 238
Ashburn 189
Santa Clara 147
Dallas 141
Beijing 138
Parma 131
Hong Kong 114
Dearborn 82
Izmir 71
Boardman 69
Ann Arbor 66
Nanjing 63
Shanghai 50
Bremen 42
Johannesburg 42
New York 42
Princeton 42
Los Angeles 39
Jacksonville 38
Munich 37
Wilmington 35
Helsinki 25
Hanoi 24
Ho Chi Minh City 24
Abidjan 22
Columbus 21
Brussels 20
Kunming 19
San Mateo 19
Shenyang 19
Düsseldorf 15
Hebei 15
Hefei 15
São Paulo 15
Nanchang 14
Seattle 13
Turku 13
Jinan 12
Toronto 12
Guangzhou 11
Jiaxing 11
Moscow 11
Tokyo 11
Changsha 10
Buffalo 9
Chennai 9
Hangzhou 9
London 9
Phoenix 8
Tianjin 8
Belo Horizonte 7
Brooklyn 7
Jakarta 7
Norwalk 7
The Dalles 7
Woodbridge 7
Boston 6
Modena 6
Montreal 6
Pune 6
Rio de Janeiro 6
Rome 6
Fremont 5
Grafing 5
Mexico City 5
Milan 5
San Francisco 5
Stockholm 5
Zhengzhou 5
Amman 4
Ankara 4
Atlanta 4
Borås 4
Brescia 4
Council Bluffs 4
Fuzhou 4
Haikou 4
Hyderabad 4
Ninh Bình 4
Nova Iguaçu 4
Nuremberg 4
Olomouc 4
Poplar 4
Shijiazhuang 4
Springfield 4
Taizhou 4
Brasília 3
Chicago 3
Curitiba 3
Denver 3
Guarulhos 3
Houston 3
Lahore 3
Manaus 3
Manchester 3
New Delhi 3
Ottawa 3
Porto Alegre 3
Totale 2.976
Salva come PNG Salva come JPEG
Nome #
Inhibition of Eph/ephrin interaction with the small molecule UniPR500 improves glucose tolerance in healthy and insulin-resistant mice 208
Dibasic biphenyl H(3) receptor antagonists: Steric tolerance for a lipophilic side chain. 186
UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. 177
Development of an orally bioavailable small molecule targeting Eph-ephrin system: in vitro and in vivo anticancer activity. 170
Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction 165
Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. 161
Discovery and development of Eph-ephrin antagonists endowed with antiangiogenic properties 149
Design and structure-activity relationship of amino acid derivatives of lithocholic acid as novel EphA2 antagonists 146
Atropisomerism and Conformational Equilibria: Impact on PI3Kδ Inhibition of 2-((6-Amino-9H-purin-9-yl)methyl)-5-methyl-3-(o-tolyl)quinazolin-4(3H)-one (IC87114) and Its Conformationally Restricted Analogs 143
Development of 3-oxo-cholenic derivatives as Eph antagonists able to block in vitro angiogenesis 138
Multiple approaches for the discovery and development of small molecules targeting Eph-ephrin protein-protein interaction 132
270 Discovery, development and optimization of low molecular weight EPH–ephrin protein–protein inhibitors 131
Toward the Definition of Stereochemical Requirements for MT(2)-Selective Antagonists and Partial Agonists by Studying 4-Phenyl-2-propionamidotetralin Derivatives. 129
Design and structure-activity relationships of amino acid derivatives of lithocholic acid as novel EphA2 receptor antagonists. 129
Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system 127
Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists 126
Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis 125
Discovery and development of low molecular weight Eph-ephrin protein-protein inhbi-tors endowed with antiangiogenic activity 120
Combining pharmacology, target hopping and computational medicinal chemistry to discover novel scaffold targeting EPH-ephrin interaction. 118
Exploiting Free-Energy Minima to Design Novel EphA2 Protein-Protein Antagonists: From Simulation to Experiment and Return 116
Metadynamics for perspective drug design: Computationally driven synthesis of new protein-protein interaction inhibitors targeting the EphA2 receptor 115
Target Hopping as a Useful Tool for the Identification of Novel EphA2 Protein–Protein Antagonists 114
Metadynamics Simulations Distinguish Short- and Long-Residence-Time Inhibitors of Cyclin-Dependent Kinase 8. 113
Free-energy studies reveal a possible mechanism for oxidation-dependent inhibition of MGL 110
New classes of potent heparanase inhibitors from ligand-based virtual screening 104
Complex product composition generates risks for generic substitution also with dosage forms for intravenous administration 102
Highly Potent and Selective MT2 Melatonin Receptor Full Agonists from Conformational Analysis of 1-Benzyl-2-acylaminomethyl-tetrahydroquinolines 101
Homology models of melatonin receptors: challenges and recent advances. 100
Computer-Aided Design of Novel Antagonists of the EphA2 Receptor 100
Synthesis and Structure-Activity Relationships of Amino Acid Conjugates of Cholanic Acid as Antagonists of the EphA2 Receptor. 99
Target-hopping: a useful approach to identify novel Eph receptor antagonists 95
ST7612AA1, a thioacetate-ω(γ-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors 95
Synthesis and characterization of new bivalent agents as melatonin- and histamine h3-ligands. 92
Synthesis of (E)-8-(3-chlorostyryl)caffeine analogs leading to 9-deazaxanthine derivatives as dual A2A antagonists /MAO-B inhibitors. 85
Recent advances in the development of melatonin MT(1) and MT(2) receptor agonists. 82
In vitro and in vivo efficacy of an orally bioavailable antagonist of Eph-ephrin system in tumor angiogenesis and growth 78
Towards the development of 5-HT7 ligands combining serotonin-like and arylpiperazine moieties 75
Structure-based virtual screening of MT2 melatonin receptor: influence of template choice and structural refinement. 71
Synthesis, structure and inhibitory activity of a stereoisomer of oseltamivir carboxylate 68
Therapeutic uses of melatonin and melatonin derivatives: a patent review (2012 - 2014) 67
MT1-Selective Melatonin Receptor Ligands: Synthesis, Pharmacological Evaluation, and Molecular Dynamics Investigation of N-[[(3-O-Substituted)anilino]alkyl]amides. 67
Kinetic analysis and molecular modeling of the inhibition mechanism of roneparstat (SST0001) on human heparanase 65
Totale 4.894
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.240
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.240
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021102 0 0 0 0 0 10 11 7 41 13 12 8
2021/2022184 6 2 3 28 2 7 8 25 7 14 16 66
2022/2023891 99 107 39 60 103 97 14 48 299 2 21 2
2023/2024288 16 27 4 13 21 61 36 24 8 14 24 40
2024/2025994 26 64 61 55 120 109 49 45 132 76 97 160
2025/20261.231 212 269 235 188 291 36 0 0 0 0 0 0
Totale 4.894